TABLE I.
Baseline characteristics of patients treated with regorafenib
| Characteristic | Value |
|---|---|
| Patients (n) | 35 |
| Sex [n (%) men] | 20 (57) |
| Age (years) | |
| Median | 61 |
| Range | 37–84 |
| Performance status [n (%)] | |
| 0 | 14 (40) |
| 1 | 20 (57) |
| 2 | 1 (3) |
| 3–4 | 0 |
| Mutation status [n (%)] | |
| KRAS | |
| Positive | 16 (46) |
| Negative | 18 (51) |
| Unknown | 1 (3) |
| NRAS | |
| Positive | 1 (3) |
| Negative | 5 (14) |
| Unknown | 29 (83) |
| BRAF | |
| Positive | 0 |
| Negative | 2 (6) |
| Unknown | 33 (94) |
| Metastasis [n (%)] | |
| Number of sites | |
| 1 | 8 (23) |
| 2 | 12 (34) |
| 3 | 11 (31) |
| ≥4 | 4 (11) |
| Location | |
| Liver | 28 (80) |
| Lung | 24 (69) |
| Lymph nodes | 12 (34) |
| Bone | 8 (23) |
| Peritoneum | 6 (17) |
| Other | 4 (11) |